A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2018
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Oct 2018 Status changed from recruiting to completed.
- 28 Jun 2018 Status changed from not yet recruiting to recruiting.
- 27 Jun 2018 New trial record